| Project/Area Number |
18K19479
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 50:Oncology and related fields
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-06-29 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2019: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2018: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 乳がん / エピゲノム / 非コードRNA / エストロゲン / エストロゲン受容体 / 細胞死 / RNA |
|---|
| Outline of Final Research Achievements |
Approximately 70% of breast cancer, which is the frequent cancer in female, is estrogen receptor (ER) positive and grows in an estrogen-dependent manner. Hormone therapy that inhibits estrogen is effective, but the problem is to acquire the therapy resistance and subsequent relapse. We have found that the ESR1 gene encoding ER is highly expressed by inducing the long noncoding RNAs (named Eleanors) from the ESR1 locus in therapy-resistant breast cancer. The purpose of this study is to establish a new application platform for the estrogen-induced apoptosis using the Eleanor RNAs as an indicator, based on the molecular mechanisms of hormone therapy resistance in breast cancer. We demonstrated that apoptosis induced by ER ligands is effective as a new therapeutic strategy in hormone therapy-resistant breast cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
女性の乳がん、男性の前立腺がんなどのホルモン依存性がんの罹患率は近年、持続的に増加傾向にある。本研究は、がんのホルモン療法抵抗性に共通する分子機序、さらに診断・評価法および治療・制御法の開発につながる学術的・社会的意義がある。
|
